Abstract
Dermatologic disease can create significant burden, interfering with relationships, daily activities, work environments, personal well-being, and physical functioning. The impact of these diseases on quality of life (QOL) can be significant, and the psychosocial impact of many dermatologic diseases is often more impactful than the physical appearance or symptoms alone. We now know that many chronic dermatologic conditions are more than skin deep, and the impact once believed to be merely superficial is as complex physiologically as it is psychosocially. Any patients that have diseases with external features may have feelings of anxiety, depression, and social isolation. Fortunately, we are learning to evaluate and treat the whole person and not just a patient’s skin. Expert dermatologic care is much more than assessing and treating the physical appearance or symptoms. Dermatologic conditions such as acne, alopecia, atopic dermatitis, psoriasis, and rosacea are unique, with differing presentations, symptoms, and psychosocial impacts. These conditions have a myriad of therapies available; however, selecting the most appropriate therapy for a given patient at a given time can be challenging, oftentimes more challenging than just establishing the correct diagnosis. In this chapter we explore how quality of life may impact dermatology patients, and how incorporating quality-of-life assessment can help providers select appropriate therapy, improving patient adherence and outcomes.
References
Karimkhani C, Dellavalle RP, Coffeng LE, Flohr C, Hay RJ, Langan SM, et al. Global skin disease morbidity and mortality: an update from the global burden of disease study 2013. JAMA Dermatol. 2017;153(5):406–12. https://doi.org/10.1001/jamadermatol.2016.5538. [Epub ahead of print]
Balieva F, Kupfer J, Lien L, Gieler U, Finlay AY, Tomas-Aragones L, et al. The burden of common skin diseases assessed with the EQ 5D: a European multi-centre study in 13 countries. Br J Dermatol. 2017;176(5):1170–8. https://doi.org/10.1111/bjd.15280. [Epub ahead of print]
Basra MK, Shahrukh M. Burden of skin diseases. Expert Rev Pharmacoecon Outcomes Res. 2009;9:271–83. https://doi.org/10.1586/erp.09.23.
Centers for Disease Control. HRQOL Concepts. 2017. https://www.cdc.gov/hrqol/concept.htm. Accessed March 6, 2017.
RAND Corporation. 36-Item short form survey instrument (SF-36). 2017. http://www.rand.org/health/surveys_tools/mos/36-item-short-form/survey-instrument.html. Accessed March 6, 2017.
Basra MK, Fenech R, Gatt RM, Salek MS, Finlay AY. The dermatology life quality index 1994-2007: a comprehensive review of validation data and clinical results. Br J Dermatol. 2008;159:997–1035. https://doi.org/10.1111/j.1365-2133.2008.08832.x. Epub 2008 Sep 15
Lewis V, Finlay AY. 10 years experience of the dermatology life quality index (DLQI). J Investig Dermatol Symp Proc. 2004;9:169–80.
Ali FM, Cueva AC, Vyas J, Atwan AA, Salek MS, Finlay AY, et al. A systematic review of the use of quality-of-life instruments in randomized controlled trials for psoriasis. Br J Dermatol. 2017;176:577–93. https://doi.org/10.1111/bjd.14788. Epub 2016 Oct 12
Chalmers JR, Simpson E, Apfelbacher CJ, Thomas KS, von Kobyletzki L, Schmitt J, et al. Report from the fourth international consensus meeting to harmonize core outcome measures for atopic eczema/dermatitis clinical trials (HOME initiative). Br J Dermatol. 2016;175:69–79. https://doi.org/10.1111/bjd.14773. Epub 2016 Jul 19
Chernyshov PV, Tomas-Aragones L, Manolache L, Marron SE, Salek MS, Poot F, et al. Quality of life measurement in atopic dermatitis. Position paper of the European Academy of Dermatology and Venereology (EADV) task force on quality of life. J Eur Acad Dermatol Venereol. 2017;31(4):576–93. https://doi.org/10.1111/jdv.14058. [Epub ahead of print]
Mattie PL, Corey KC, Kimball AB. Psoriasis area severity index (PASI) and the dermatology life quality index (DLQI): the correlation between disease severity and psychological burden in patients treated with biological therapies. J Eur Acad Dermatol Venereol. 2014;28:333–7. https://doi.org/10.1111/jdv.12106. Epub 2013 Feb 21
Takeshita J, Callis Duffin K, Shin DB, Krueger GG, Robertson AD, Troxel AB, et al. Patient-reported outcomes for psoriasis patients with clear versus almost clear skin in the clinical setting. J Am Acad Dermatol. 2014;71:633–41. https://doi.org/10.1016/j.jaad.2014.05.001. Epub 2014 Jun 11
Chung J, Callis Duffin K, Takeshita J, Shin DB, Krueger GG, Robertson AD, et al. Palmoplantar psoriasis is associated with greater impairment of health-related quality of life compared with moderate to severe plaque psoriasis. J Am Acad Dermatol. 2014;71:623–32. https://doi.org/10.1016/j.jaad.2014.04.063. Epub 2014 Jun 2
Ryan C, Sadlier M, De Vol E, Patel M, Lloyd AA, Day A, et al. Genital psoriasis is associated with significant impairment in quality of life and sexual functioning. J Am Acad Dermatol. 2015;72:978–83. https://doi.org/10.1016/j.jaad.2015.02.1127. Epub 2015 Mar 29
Wade AG, Crawford GM, Young D, Leman J, Pumford N. Severity and management of psoriasis within primary care. BMC Fam Pract. 2016;17:145.
Lebwohl MG, Bachelez H, Barker J, Girolomoni G, Kavanaugh A, Langley RG, et al. Patient perspectives in the management of psoriasis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey. J Am Acad Dermatol. 2014;70:871–81.e1-30. https://doi.org/10.1016/j.jaad.2013.12.018. Epub 2014 Feb 24
Belinchon I, Rivera R, Blanch C, Comellas M, Lizan L. Adherence, satisfaction and preferences for treatment in patients with psoriasis in the European Union: a systemic review of the literature. Patient Prefer Adherence. 2016;10:2357–67. eCollection 2016
Hagg D, Sundstrom A, Eriksson M, Schmitt-Egenolf M. Decision for biological treatment in real life is more strongly associated with the psoriasis area and severity index (PASI) than with the dermatology life quality index (DLQI). J Eur Acad Dermatol Venereol. 2015;29:452–6. https://doi.org/10.1111/jdv.12576. Epub 2014 Jun 9
Rencz F, Kemeny L, Gajdacsi JZ, Owczarek W, Arenberger P, Tiplica GS, et al. Use of biologics for psoriasis in Central and Eastern European countries. J Eur Acad Dermatol Venereol. 2015;29(11):2222–30. https://doi.org/10.1111/jdv.13222. Epub 2015 Sep 14
Basra MK, Chowdhury MM, Smith EV, Freemantle N, Piguet V. Quality of life in psoriasis and chronic hand eczema: the discrepancy in the definition of severity in NICE guidelines and its implications. Br J Dermatol. 2012;166:462–3. https://doi.org/10.1111/j.1365-2133.2011.10601.x. Epub 2011 Dec 5
Rencz F, Baji P, Gulacsi L, Karpati S, Pentek M, Poor AK, et al. Discrepancies between the dermatology life quality index and utility scores. Qual Life Res. 2016;25:1687–96. https://doi.org/10.1007/s11136-015-1208-z. Epub 2015 Dec 18
Meeuwis KA, de Hullu JA, van de Nieuwenhof HP, Evers AW, Massuger LF, van de Kerkhof PC, et al. Quality of life and sexual health in patients with genital psoriasis. Br J Dermatol. 2011;164:1247–55. https://doi.org/10.1111/j.1365-2133.2011.10249.x. Epub 2011 May 13
Meeuwis KA, van de Kerkhof PC, Massuger LF, Massuger LF, de Hullu JA, van Rossum MM. Patients experience of psoriasis in the genital area. Dermatology. 2012;224:271–6. https://doi.org/10.1159/000338858. Epub 2012 Jun 4
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer International Publishing AG
About this chapter
Cite this chapter
Cather, J., Cather, J.C., Young, M. (2018). Quality of Life in the Dermatology Practice. In: Yamauchi, P. (eds) Biologic and Systemic Agents in Dermatology. Springer, Cham. https://doi.org/10.1007/978-3-319-66884-0_5
Download citation
DOI: https://doi.org/10.1007/978-3-319-66884-0_5
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-66883-3
Online ISBN: 978-3-319-66884-0
eBook Packages: MedicineMedicine (R0)